Open Access. Powered by Scholars. Published by Universities.®

Digital Commons Network

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 2 of 2

Full-Text Articles in Entire DC Network

Examination Of Methamphetamine Reinstatement In Female And Male Rats: A Pre-Clinical Model Of Relapse, Steven T. Pittenger Jun 2016

Examination Of Methamphetamine Reinstatement In Female And Male Rats: A Pre-Clinical Model Of Relapse, Steven T. Pittenger

Department of Psychology: Dissertations, Theses, and Student Research

Methamphetamine (meth) dependence is often characterized by persistent and chronic relapse (i.e., return to drug use). There is growing pre-clinical and human evidence suggesting females are at greater risk to relapse. The set of studies presented in this dissertation extended this limited evidence by identifying sex-dependent neural substrates correlated with meth-triggered reinstatement (Experiment 1) and by examining sex-differences in reinstatement triggered by drugs of abuse that are commonly co-abused with meth (Experiment 2). Female and male rats were trained to self-administer meth, received subsequent extinction sessions, and then tested for reinstatement. In Experiment 1, rats were perfused following reinstatement testing …


Iptakalim Preferentially Decreases Nicotine-Induced Hyperlocomotion In Phencyclidine-Sensitized Rats: A Potential Dual Action Against Nicotine Addiction And Psychosis, Nick Volf, Gang Hu, Ming Li Jan 2012

Iptakalim Preferentially Decreases Nicotine-Induced Hyperlocomotion In Phencyclidine-Sensitized Rats: A Potential Dual Action Against Nicotine Addiction And Psychosis, Nick Volf, Gang Hu, Ming Li

Department of Psychology: Faculty Publications

Objective: Iptakalim is a putative ATP-sensitive potassium (KATP) channel opener. It is also a novel nicotinic acetylcholine receptor (nAChR) blocker and can antagonize nicotine-induced increase in dopamine release in the nucleus accumbens. Our recent work also shows that iptakalim exhibits a clozapine-like atypical antipsychotic profile, indicating that iptakalim may possess a dual action against nicotine addiction and schizophrenia.

Methods: The present study examined the potential therapeutic effects of iptakalim on nicotine use in schizophrenia. We created an animal model of comorbidity of nicotine addiction and schizophrenia by injecting male Sprague-Dawley rats with nicotine (0.40 mg/kg, subcutaneously[sc]) or saline, in combination …